Recipharm completes Korean serialisation project for Abbott as the CDMO continues international roll out

Recipharm, the leading contract development and manufacturing organisation (CDMO), is pleased to announce further serialisation success with the completion of a complex serialisation project for Korea for one of its leading customers; Abbott. The initiative, which commenced in April 2014, is now completed.

The CDMO met the precise customer and market requirement to produce a data matrix code, including serial number, with full compliance with complex regulations, similar to foreseen EU rules.

Recipharm applied its internationally adaptable solution, designed to achieve full compliance with country specific regulations, to a blister packaging line; with the need differing markedly from Chinese serialisation. Validation batches are now manufactured released and planned to be shipped to Korea mid-March 2015.

Recipharm applied its successful methodology to the project initiated for the top ten pharmaceutical customer. From the outset, integration formed a key tenet with the establishment of joint company strategic teams and the sharing of critical information. Costs were kept to a minimum and full implementation achieved.

Stephane Guisado, General Manager at Recipharm in Fontaine commented: "We are delighted with the success of this serialisation project for the Korean market carried out for Abbott, a long standing pharma partner of ours. Once again, our serialisation platform solution has proved the extent of its adaptability and resourcefulness for differing geographic and multi-country regulatory requirements. Indeed, in this case, it ensured that our customer complied in full with the relevant serialisation regulations set down by Korea."

He continued: "We were pleased to have received such strong thanks and recognition from the Abbott project team for the work that we staged on this project. We look forward to rolling out further projects during 2015."

Contact information
Stephane Guisado, General Manager Recipharm Fontaine, [email protected],
+ 33 3 8044 78 33
Amine Tahiri, Commercial Manager Recipharm Fontaine, [email protected],
+ 33 8044 78 05
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or [email protected]
Tel: +44 (0) 207 861 3019/3043

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com


Tristan Jervis
Managing Partner

DF logo
Holborn Gate, 26 Southampton Buildings
London WC2A 1BP

Telephone: +44 (0)207 203 6742
Direct: +44 (0)207 203 6740
E-mail: [email protected]
www.defacto.com

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.